The directors who actually bought stock post IPO did so between 18-22 November for averages of 67.5c - 72.1c. Maybe one of them paid <60c for some shares - but I doubt it. Given the complete lack of buying since, their purchases look a lot like token efforts to demonstrate support post IPO.
In my view you are dead right about Tony, and also about TIS burning a lot of investors who might otherwise be interested in TRP. And, that the cash is never going to hit holders' back pockets; it's going to be spent so that holders end up with either a zero or a hero, something of which no-one can complain - it's not as though that has been kept a secret! And, I agree fully that sentiment about biotechs is currently poor.
But none of that impacts on my primary point: TRP can do vastly better when it comes to self-promotion. Its failure to do so falls at the feet of the directors.
FD
TRP Price at posting:
42.5¢ Sentiment: Buy Disclosure: Held
